(A) Distribution of 28 gene sets, including 15 immune cell gene sets and 13 immune function gene sets. (B) Spearman correlation analysis revealed the correlation of P2RY13 as well as immune and stromal scores with 28 gene sets. (C) Spearman correlation analysis revealed the correlation of P2RY13 with 11 immunomodulators. (D and E) Relative probabilities to respond to anti-programmed cell death protein 1/programmed death-ligand 1 and anti-cytotoxic T-lymphocyte-associated protein four treatment in patients with lung adenocarcinoma with high and low P2RY13 expression. The data are presented as the mean standard deviation, and were compared with Wilcoxon signed-rank test. aDCs, activated dendritic cells; iDCs, immature DCs; pDCs, plasmacytoid DCs; Tfh, T follicular helper cells; Th1, type 1 helper; Th2, type 2 helper; TILs, tumor-infiltrating lymphocytes; Tregs, regulatory T cells; HLA, human leukocyte antigen; CCR, C-C chemokine receptor; APCs, antigen presenting cells; MHC, major histocompatibility complex; IPS, immunophenoscore; P2RY13, P2Y purinoceptor 13.